WaveMan
WaveMan · Company
VOR · Vor Biopharma Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VOR Vor Biopharma (VOR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001817229
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
74
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $12.0K priced

What the filings say about VOR

Insiders, 180 days
-$4.2K net sold
1 seller · 0% of sales under a 10b5-1 plan

Vor Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vor Biopharma Inc. insiders sold a net $4.2K of stock across 95 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
RA CAPITAL MANAGEMENT, L.P.
SELL
2026-07-21 SECtraded 2026-07-16
213
$4.2K
-6.0%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Apr 20, 2026.
  • The trade is 0.0% of the 4,501,882 shares held after it.
  • No other insider sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. sold about $4.2K of VOR on Jul 16, 2026; 74 funds added in the latest 13F quarter.
Shah Rajeev M.
Director
SELL
2026-04-24 SECtraded 2026-04-22
165,150
$2.6M
+29.8%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Apr 10, 2026.
  • The trade is 6.9% of the 2,402,095 shares held after it.
  • 2 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shah Rajeev M. sold about $2.6M of VOR on Apr 22, 2026; 2 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-21 SECtraded 2026-04-20
171,963
$2.7M
+19.6%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Apr 17, 2026.
  • The trade is 6.7% of the 2,567,245 shares held after it.
  • 2 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. sold about $2.7M of VOR on Apr 20, 2026; 2 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-21 SECtraded 2026-04-17
458,411
$7.5M
+19.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Apr 15, 2026.
  • The trade is 16.7% of the 2,739,208 shares held after it.
  • 2 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. sold about $7.5M of VOR on Apr 17, 2026; 2 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-15 SEC
53,644
$858.8K
+22.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Apr 14, 2026.
  • The trade is 1.7% of the 3,197,619 shares held after it.
  • 2 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. sold about $858.8K of VOR on Apr 15, 2026; 2 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
95 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 90 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.2K over 180 days
-$4.2K of it by a 10%+ holder
more than 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
74 funds bought in last quarter
more than 58% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
21.0% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
more than 80% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VOR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-30.8%12M
-74%-47%-21%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-04-06 · Kolchinsky Peter sold $8.9M2026-04-13 · RA CAPITAL MANAGEMENT, L.P. sold $8.6M2026-04-17 · RA CAPITAL MANAGEMENT, L.P. sold $7.5M2025-10-29 · Kolchinsky Peter sold $6.3M2026-04-08 · Shah Rajeev M. sold $5.8M2026-04-02 · Kolchinsky Peter sold $4.7M2026-04-20 · RA CAPITAL MANAGEMENT, L.P. sold $2.7M2026-04-22 · Shah Rajeev M. sold $2.6M2025-10-27 · RA CAPITAL MANAGEMENT, L.P. sold $2.6M2026-04-14 · RA CAPITAL MANAGEMENT, L.P. sold $2.5M2025-10-28 · Kolchinsky Peter sold $2.4M2026-04-09 · Shah Rajeev M. sold $2.2M2026-04-08 · Shah Rajeev M. sold $2.2M2025-10-23 · RA CAPITAL MANAGEMENT, L.P. sold $2.2M2025-10-24 · RA CAPITAL MANAGEMENT, L.P. sold $1.5M2025-10-28 · Kolchinsky Peter sold $1.0M2026-04-15 · RA CAPITAL MANAGEMENT, L.P. sold $858.8K2026-04-06 · Kolchinsky Peter sold $774.2K2025-10-30 · Kolchinsky Peter sold $617.4K2026-04-06 · Kolchinsky Peter sold $125.3K2026-04-02 · Kolchinsky Peter sold $29.1K2026-04-10 · Shah Rajeev M. sold $13.0K2026-07-16 · RA CAPITAL MANAGEMENT, L.P. sold $4.2K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VOR: institutional holders (13F)

13F holdings, latest reported quarter
TCG Crossover Management, LLC
5,673,078 sh
$104.4M
FMR LLC
4,932,149 sh
$90.8M
FCPM III SERVICES B.V.
4,117,354 sh
$75.8M
BlackRock, Inc.
3,468,107 sh
$63.8M
Venrock Adviser, LLC
3,041,719 sh
$56.0M

Congress trades in VOR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VOR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

VOR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$457.8K position · as of 2026-07-31
1.0%
Select Biotechnology Portfolio
$17.8M position · as of 2026-05-31
0.3%
Fidelity Advisor Biotechnology Fund
$7.3M position · as of 2026-07-31
0.3%
Fidelity Small Cap Discovery Fund
$7.4M position · as of 2026-07-31
0.3%
Fidelity Series Small Cap Discovery Fund
$6.3M position · as of 2026-07-31
0.3%
Fidelity Small Cap Growth Fund
$26.9M position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 3
2 active
1
Not applicable
0 active
2
Multi-phase
0 active
What changed recently
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
2026-10-16 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $4.2K sold by insiders over 180 days, 74 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VOR financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$140.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
+182.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-48.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
0.10x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
-13.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$371.6M-$121.2M-$126.0M-$93.4M
Net income-$696.0M-$116.9M-$117.9M-$92.1M
EPS (diluted)-70.50-34.03-1.75-2.33
Operating cash flow-$142.7M-$99.7M-$100.3M-$85.1M
Cash$396.5M$81.9M$31.4M$57.7M
Dividends paid$0$0$0$0
SEC XBRL, fiscal years, as known on 2026-10-27

VOR Stock Sonar score 4/7 axes

Find similar shapesCompare

VOR ranks highest on profitability (75th percentile) and institutional and government (58th), and lowest on risk and compliance (13th), among Pharma & Biotech peers.

Profitability
75
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets+182.9% · 99 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-48.8% · 52 pct, sector of 576
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4K · 61 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
58
Inputs
  • Funds adding, latest quarter74 · 58 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
13
Inputs
  • Short interest, % of float+21.0% · 13 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VOR filings, in plain words

Are Vor Biopharma insiders buying or selling VOR?

In the 180 days to 2026-10-27, Vor Biopharma insiders were net sellers, a net $4.2K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-27, Vor Biopharma insiders were net sellers of VOR, a net $4.2K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $4.2K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies